The board of directors of Sihuan Pharmaceutical Holdings Group Ltd. announced that the Group's Cinepazide Maleate Injection (Kelinao 2ml: 80mg per unit and Anjieli 10ml: 320mg per unit) for the treatment of new indication of acute ischemic stroke has successfully obtained the approval from the National Medical Products Administration ("NMPA") of the People's Republic of China (China) at the end of 2020. The Cinepazide Maleate Injection (Kelinao) of the Group is currently the only approved drug in the field of stroke treatment since the commencement of the domestic post-marketing clinical study for drugs. Cinepazide Maleate Injection (Kelinao) is a kind of weak calcium ion antagonist with a unique synergism of endogenous adenosine, and it can effectively improve the blood supply in the cerebral ischemic area. As the first marketed Cinepazide Maleate Injection in China, Kelinao® has been widely used in the treatment of cardiovascular, cerebrovascular and peripheral vascular diseases since 2002, and accumulated clinical use experience of more than 6 million people, which demonstrated a good safety profile.